Adverse Event Reporting
| VAERS ID | 2484714 |
|---|---|
| Gender | Male |
| Age | 22 |
| StateCode | FR |
| Pharmaceutical Company | MODERNA |
| Lot Number | |
| Number of vaccinations | |
| Vaccinated | 2021-04-23 |
| Onset | 2022-05-18 |
| Condition | Permanent Disability |
Symptoms
- Pain in extremity
- Hypoaesthesia
- Back pain
- Neck pain
Current Illness
Preexisting Conditions
Other Medications
Previous Vaccinations
Allergies
Laboratory Data
Write-up
Lumbar pain; upper and lower limb pain; upper and lower limb numbness; Cervical pain; This case was received via Regulatory Authority.
This regulatory authority case was reported by a consumer and describes the occurrence of BACK PAIN (Lumbar pain), PAIN IN EXTREMITY (upper and lower limb pain), HYPOAESTHESIA (upper and lower limb numbness) and NECK PAIN (Cervical pain) in a 22-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 immunisation.
No Medical History information was reported.
On 23-Apr-2021, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form.
On 18-May-2022, the patient experienced BACK PAIN (Lumbar pain) (seriousness criterion disability), PAIN IN EXTREMITY (upper and lower limb pain) (seriousness criterion disability), HYPOAESTHESIA (upper and lower limb numbness) (seriousness criterion disability) and NECK PAIN (Cervical pain) (seriousness criterion disability).
At the time of the report, BACK PAIN (Lumbar pain), PAIN IN EXTREMITY (upper and lower limb pain), HYPOAESTHESIA (upper and lower limb numbness) and NECK PAIN (Cervical pain) had not resolved.
The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.
No concomitant medications were reported.
Dosage text reported as one administration.
No treatment information was provided.
Company comment: This regulatory authority case concerns a 22-year-old, male patient with no medical history information reported, who experienced the unexpected serious (disabling) event of back pain, pain in extremity (upper and lower limb pain), hypoesthesia (upper and lower limb numbness) and neck pain.
The events occurred approximately 25 days after a dose of mRNA-1273.
No information about dose number or vaccination schedule was provided.
Events were not resolved.
No further information about the events was provided.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
; Sender's Comments: This regulatory authority case concerns a 22-year-old, male patient with no medical history information reported, who experienced the unexpected serious (disabling) event of back pain, pain in extremity (upper and lower limb pain), hypoesthesia (upper and lower limb numbness) and neck pain.
The events occurred approximately 25 days after a dose of mRNA-1273.
No information about dose number or vaccination schedule was provided.
Events were not resolved.
No further information about the events was provided.
The benefit-risk relationship of mRNA-1273 is not affected by this report.